Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Equivalents Common Equity Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Lisata Therapeutics (LSTA) Long-Term Deferred Tax (2017 - 2018)

Lisata Therapeutics filings provide 4 years of Long-Term Deferred Tax readings, the most recent being $575055.0 for Q1 2018.

For the quarter ending Q1 2018, Long-Term Deferred Tax changed N/A year-over-year to $575055.0, compared with a TTM value of $575055.0 through Mar 2018, changed N/A, and an annual FY2017 reading of $575000.0, changed N/A over the prior year.
Long-Term Deferred Tax hit $575055.0 in Q1 2018 for Lisata Therapeutics, roughly flat from $575000.0 in the prior quarter.
The five-year high for Long-Term Deferred Tax was $575055.0 in Q1 2018, with the low at $575000.0 in Q4 2017.